Women who’ve been injured by a defective transvaginal mesh surgical device may soon see some legal justice.
There is currently one trial underway involving a victim of the Gynecare Prolift System, a transvaginal mesh device manufactured by Ethicon, a division of Johnson & Johnson. Next week, a victim of the C.R. Bard Avaulta transvaginal mesh device will have their case go to trial.
These are the first of thousands of claims pending in courts across the country which blame transvaginal mesh devices for an array of serious injuries that have caused recipients to undergo numerous corrective surgeries and still have left them facing a lifetime of pain. There are at least 1,800 lawsuits filed against Ethicon in one state court, alone.
In addition to the injury claims, plaintiffs in these lawsuits believe that Ethicon hid evidence that its Gynecare Prolift devices were dangerous and likely to cause recipients severe pain and some permanent injuries.
The results of this ongoing bellwether trial likely will weigh heavily on the fate of those other lawsuits. The same impact can be expected from the bellwether trial involving the victim of the Avaulta transvaginal mesh device.
Transvaginal mesh devices, including Gynecare Prolift and Avaulta, were approved through the Food and Drug Administration’s flawed 510(k) “fast-track” approval system. This process allows new medical devices onto the market without having to endure pre-market safety testing. Plaintiffs allege that Ethicon knowingly hid evidence that its Gynecare Prolift device were dangerous and causing women to suffer severe pain and life-altering injuries.